Summary of Purpose
This study is a single-centre prospective post-market approval of the early experience with the Watchman FLX device for left atrial appendage closure in patients with atrial fibrillation at high risk of thromboembolic stroke and with contraindications to long-term oral antocoagulation therapy.Read More →
The following dates are available for this trial. Trial information last updated on 7 November 2017.
|1 Jan 2016||15 Mar 2017||1 Jun 2016||1 Jun 2016||1 Mar 2017||Unavailable|
|Start Date||First Received||1st Completion||Completion||Verification||Results|